I hope Sanofi is not passing up this opportunity to its competitors. They have excellent products like ViaTab as well.
The company has said that it cannot afford to bring VIAject to market by itself and will be looking for a partner from Big Pharma in the coming year. Leerink Swann’s Schimmer thinks that Sanofi-Aventis (SNY) will be an ideal partner for the little biotech. “Sanofi has the best selling long-acting insulin, Lantus, but its fast-acting insulin, Apidra, has fared poorly in the marketplace. By substituting VIAject for Apidra, Sanofi can offer a more compelling combination of ultra-fast and long acting insulins,” wrote Schimmer.